Remove tag cost
article thumbnail

ICER updates cost-effectiveness threshold for bluebird, Vertex and CRISPR's dueling sickle cell gene therapies

Fierce Pharma

The potentially curative promise of gene therapies often carries a steep price tag. | The potentially curative promise of gene therapies often carries a steep price tag. But for a pair of personalized medicine prospects in sickle cell disease (SCD), the cost could be worth it, at least as far as ICER is concerned.

article thumbnail

Pharma running online ads on vaccine misinformation sites

World of DTC Marketing

NewsGuard found that 67% of the COVID misinformation sites had Google advertising tags and 30% had tags from The Trade Desk. It was estimated that the costs related to digital advertising fraud worldwide would grow exponentially within the four years between 2018 and 2022, from 19 billion to 44 billion U.S. How much is enough?

Pharma 180
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Medicare savings won’t make a dent in healthcare costs

World of DTC Marketing

SUMMARY: Allowing Medicare to negotiate drug prices is popular with voters because the media has been focused on the high price of some drugs, but this measure won’t lead to lower healthcare costs. New technologies are being developed that allow for virtual clinical trials and other cost-lowering development costs.

article thumbnail

The current pharma business model is unsustainable

World of DTC Marketing

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. Rather than investing more in R&D, most pharma companies feel its more cost-effective to buy small biotech companies developing unique molecules that can find a market niche.

Pharma 210
article thumbnail

bluebird bio wins back-to-back landmark FDA approvals for first-in-class gene therapies

Pharmaceutical Technology

Spark Therapeutics’ Luxturna, indicated for inherited retinal disease (IRD), was the first gene therapy to be approved, in 2017, with a price tag of $850,000 for each eye. Prior to bluebird's approvals, there were only two FDA-approved gene therapies for inherited conditions on the market.

FDA 115
article thumbnail

Healthcare doesn’t give a damn about patients

World of DTC Marketing

Pfizer, for instance, hiked the cost of its leukemia medication Besponsa again this month, bringing its per-vial price tag to $21,056. Of course, Mitch is worth $35 million, so he’he’llver have to worry about the high cost of healthcare. Will the industry ever develop a conscience?

article thumbnail

Critical Success Factors for Commercializing Specialty Drugs, Cell and Gene Therapies

Pharmacy Times

Although payers have become somewhat accustomed to the high cost of specialty drugs, the price tags for gene therapies are causing “sticker shock.”

49